Imbioray (hangzhou) Biomedicine Co., Ltd.
Clinical trials sponsored by Imbioray (hangzhou) Biomedicine Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cell therapy combo aims to boost kidney cancer treatment Results expected Dec 2026 (estimated)
- Immune cell injection takes on Hard-to-Treat leukemia Results expected Jul 2027 (estimated)
- Immune cells engineered to fight lymphoma enter human testing Results expected Jul 2027 (estimated)